Using a new drug to help control HIV infection
Modulation of BRD4 to epigenetically suppress HIV
['FUNDING_R01'] · UNIVERSITY OF TEXAS MED BR GALVESTON · NIH-11092751
This study is looking at how a new drug called ZL0580 can help fight HIV by targeting a protein in your body, and it’s for people living with HIV who want to see if this treatment can lower the virus and improve their immune system.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS MED BR GALVESTON (nih funded) |
| Locations | 1 site (GALVESTON, UNITED STATES) |
| Trial ID | NIH-11092751 on ClinicalTrials.gov |
What this research studies
This research investigates how a specific drug can modulate a protein called BRD4 to suppress HIV infection. By targeting the host's cellular mechanisms, the study aims to disrupt the latent HIV infection that hides in the body. The approach involves using a small molecule, ZL0580, which has shown promise in reducing HIV activity in various cell models, including immune cells. Patients may be monitored for changes in HIV levels and overall immune response as part of this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV, particularly those with latent infections.
Not a fit: Patients who are HIV-negative or those who do not have a latent HIV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for controlling HIV and potentially reducing the viral load in patients.
How similar studies have performed: Previous research has shown that targeting BRD4 can activate HIV transcription, indicating a promising avenue for further exploration.
Where this research is happening
GALVESTON, UNITED STATES
- UNIVERSITY OF TEXAS MED BR GALVESTON — GALVESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HU, HAITAO — UNIVERSITY OF TEXAS MED BR GALVESTON
- Study coordinator: HU, HAITAO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus